Plasmodium vivax is an important cause of malaria, associated with a significant public
health burden. Whilst enhanced malaria-control activities have successfully reduced the …

Drug response varies between individuals owing to disease heterogeneity, environmental
factors, and genetic factors. Genetic factors can affect both the pharmacokinetics and …

Background The undetectable hypnozoite reservoir for relapsing Plasmodium vivax and P.
ovale malarias presents a major challenge for malaria control and elimination in endemic …

Although global efforts in the past decade have halved the number of deaths due to malaria,
there are still an estimated 219 million cases of malaria a year, causing more than half a …

Malaria elimination will be possible only with serious attempts to address asymptomatic
infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax …

Background Primaquine is the only licensed drug for eradicating Plasmodium vivax
hypnozoites and, therefore, preventing relapses of vivax malaria. It is a vital component of …

The hypnozoite reservoir of Plasmodium vivax represents both the greatest obstacle and
opportunity for ultimately eradicating this species. It is silent and cannot be diagnosed until it …

Challenges in classifying recurrent Plasmodium vivax infections constrain surveillance of
antimalarial efficacy and transmission. Recurrent infections may arise from activation of …

Plasmodium vivax radical cure requires the use of primaquine (PQ), a drug that induces
haemolysis in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals, which …

A barrier to eliminating Plasmodium vivax malaria is inadequate treatment of infected
patients. 8-Aminoquinoline–based drugs clear the parasite; however, people with glucose-6 …